If you would like to learn more about future focusIR related events and roundtables, please submit your details here

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksSyncona Regulatory News (SYNC)

Share Price Information for Syncona (SYNC)

Share Price is delayed by 15 minutes
Get Live Data
109.80    1.60 (1.48%)
Bid:
108.60
Ask:
109.20
Spread: 0.60 (0.552%)
Market Cap: £667.80m
SYNC Live PriceLast checked at - London Stock Exchange

Intraday Syncona Share Chart

Director Declaration

22 Jun 2022 17:21

RNS Number : 8659P
Syncona Limited
22 June 2022
 

Syncona Limited (the "Company")

Director Declaration

 

22 June 2022

In accordance with the requirements of the Listing Rule 9.6.14R, the Company advises the following change to directorships in other publicly quoted companies, held by the following member of the Board:

Virginia Holmes was appointed to Murray International Trust PLC on 22 June 2022.

Enquiries

Syncona Ltd

Andrew Cossar

Tel: +44 (0) 20 3981 7940

 

Citco Fund Services (Guernsey) Limited

Company Secretary

Tel: +44 (0) 1481 758200

 

About Syncona:

Syncona is a leading FTSE250 healthcare company whose purpose is to invest to extend and enhance human life by founding and building a portfolio of global leaders in life science to deliver transformational treatments to patients in areas of high unmet need.

Our strategy is to found, build and fund companies around exceptional science to create a diversified portfolio of 15-20 globally leading healthcare businesses for the benefit of all our stakeholders. We focus on developing treatments for patients by working in close partnership with world-class academic founders and management teams. Our balance sheet underpins our strategy enabling us to take a long-term view as we look to improve the lives of patients with no or poor treatment options, build sustainable life science companies and deliver strong risk-adjusted returns to shareholders.

Copies of this press release, a company results presentation, and other corporate information can be found on the company website at: www.synconaltd.com 

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
RDNQLLFLLQLLBBB
Date   Source Headline
28th Jun 201912:33 pmRNS2019 Dividend Scrip Reference Price
27th Jun 201911:44 amRNSPublication of Annual Report and Notice of AGM
27th Jun 20197:00 amRNSSale of Blue Earth Diagnostics to Bracco Imaging
21st Jun 20194:18 pmRNSDirector Information
13th Jun 20192:27 pmRNSDividend Announcement
13th Jun 20197:00 amRNSAnnual Financial Report
4th Jun 20197:00 amRNSAppointment of Chair-Designate and NED
20th May 20197:00 amRNSSyncona founds Quell with £35m Series A Financing
14th May 201912:00 pmRNSAutolus reports Q1 2019 Financial Results
7th May 20197:00 amRNSBED announces initial clinical experience of PSMA
16th Apr 20197:00 amRNSAutolus announces closing of public offering
11th Apr 20197:09 amRNSAutolus announces pricing of public offering
11th Apr 20197:00 amRNSCreation of leading retinal gene therapy platform
9th Apr 20197:00 amRNSAutolus announces launch of proposed offering
1st Apr 20196:14 pmRNSAutolus presents initial AUTO1 adult ALL data
27th Mar 201911:12 amRNSDirector/PDMR Shareholding
26th Mar 201910:18 amRNSAutolus hosts R&D day and updates on AUTO3
20th Mar 20194:27 pmRNSDirector/PDMRs Shareholding
19th Mar 20195:48 pmRNSStandard form for notification of major holdings
19th Mar 20194:44 pmRNSDirectors/PDMR Shareholdings
18th Mar 20194:15 pmRNSNotification of Major Holdings
13th Mar 20194:55 pmRNSResults of Placing in Syncona Limited
13th Mar 20197:00 amRNSProposed Placing in Syncona Limited
12th Mar 20197:00 amRNSUpdate on management of strategic capital pool
4th Mar 20197:11 amRNSNightstar agreement to be acquired by Biogen
26th Feb 20197:00 amRNSSyncona leads CHF 35 million financing in Anaveon
19th Feb 201911:52 amRNSAutolus announces Results from CARPALL Trial
13th Feb 20197:00 amRNSQuarterly Update
16th Jan 20197:00 amRNSAppointment of Joint Corporate Broker
17th Dec 201812:38 pmRNSChange of Registered Office - Released in Error
17th Dec 201811:47 amRNSChange of Registered Office
4th Dec 20187:00 amRNSFreeline presents data at the ASH Annual Meeting
3rd Dec 20187:00 amRNSAutolus announces update on AUTO4 and AUTO5
3rd Dec 20187:00 amRNSAutolus presents AUTO3 data at ASH Annual Meeting
26th Nov 20189:57 amRNSAutolus publishes Annual Report
21st Nov 20187:10 amRNSInterim Results
13th Nov 20187:00 amRNSNightstar reports Q3 2018 financial results
1st Nov 20181:40 pmRNSAutolus Therapeutics to Present New Data at ASH
1st Nov 20181:36 pmRNSFreeline releases initial data for FLT180a
1st Nov 20187:00 amRNSDirector Information
30th Oct 201811:24 amRNSResult of Extraordinary General Meeting
4th Oct 20187:00 amRNSPublication of EGM Circular
3rd Oct 20187:00 amRNSNightstar closes public offering
28th Sep 20187:00 amRNSNightstar announces pricing of public offering
24th Sep 20187:00 amRNSNightstar reports positive proof of concept data
3rd Sep 201811:22 amRNSChange of Administrator and Depositary
31st Aug 20184:08 pmPRNTotal Voting Rights
13th Aug 201812:39 pmPRNIssue of shares pursuant to the Long Term Incentive Plan
13th Aug 201811:11 amPRNNightstar reports Q2 2018 financial results
9th Aug 20187:00 amPRNSyncona Limited Quarterly Update

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.